文献速递前列腺癌

寡进展性去势抵抗性前列腺癌的进展导向治疗

Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2019-09-23

这项双机构回顾性研究纳入30例接受ADT(联合或不联合二线全身治疗)期间出现寡进展的mCRPC患者,对进展病灶行进展导向治疗(PDT)并维持原全身治疗。中位无下一线全身治疗生存期为16个月(95%CI 10-22),中位无进展生存期为10个月(95%CI 6-15),放疗或手术相关毒性仅为轻度。

要点

  • 对mCRPC寡进展病灶行手术或高剂量放疗,可推迟下一线全身治疗
  • 中位无下一线全身治疗生存期16个月(95%CI 10-22)
  • 中位无进展生存期10个月(95%CI 6-15),毒性仅为轻度

核心结论

  • 对mCRPC寡进展病灶行PDT并维持原全身治疗,可显著推迟下一线全身治疗的启动,值得进一步开展前瞻性试验。

研究设计与样本

  • 双机构回顾性研究,共纳入30例mCRPC且出现寡进展的患者。
  • 寡进展定义为进展病灶总数≤3个,可位于已知转移部位和/或出现新发转移和/或局部复发。
  • 所有患者均在ADT联合或不联合二线全身治疗下接受针对寡进展病灶的PDT,并维持原全身治疗。

主要发现

  • 中位无下一线全身治疗生存期为16个月(95%CI 10-22)。
  • 中位无进展生存期为10个月(95%CI 6-15)。
  • 仅见轻度放疗或手术相关毒性。

临床怎么用

  • 对全身治疗控制稳定、仅有限病灶进展的mCRPC患者,可考虑对寡进展病灶行手术或高剂量放疗以推迟换药。

局限性

  • 回顾性设计、样本量仅30例,结论需前瞻性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In metastatic castration-refractory prostate cancer (mCRPC), state-of-the-art treatment consists of androgen biosynthesis inhibition (abiraterone), inhibition of the androgen receptor (enzalutamide), chemotherapy, or radium-223 in combination with androgen deprivation therapy (ADT). A subgroup of these patients show oligoprogression, with the progression of only a limited number of metastatic spots, while all other metastases remain controlled by ongoing systemic therapy. In a bi-institutional retrospective study, we tested the hypothesis that progression-directed therapy (PDT) targeting oligoprogressive lesions might defer the initiation of next-line systemic treatment (NEST). A total of 30 patients were diagnosed with mCRPC and experienced oligoprogression, defined as a total of three or fewer progressive lesions either at known metastatic sites and/or the appearance of new metastasis and/or local recurrence. All patients were under active ADT with or without second-line systemic treatment. All patients received PDT targeting the oligoprogressive lesions, while ongoing systemic treatment was maintained. There was median NEST-free survival of 16mo (95% confidence interval [CI] 10-22) and progression-free survival of 10mo (95% CI 6-15) with only minor radiotherapy- or surgery-related toxicity. These findings encourage further prospective trials. PATIENT SUMMARY: In patients with metastatic castration-refractory prostate cancer, surgical treatment or high-dose radiation therapy directed to only the limited number of progressive metastatic spots, while all other metastases remained controlled by ongoing systemic therapy, led to substantial postponement of next-line systemic treatment in our study.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Berghen C, Joniau S, Ost P, et al. Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31558422. doi:10.1016/j.euo.2019.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。